Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis

• The number and percentage of subjects in each treatment group recorded as a clinical cure or failure or indeterminate. [ Time Frame: Multiple visits up until the Late Follow Up (28-35 Days after completion of study drug administration) ] [ Designated as safety issue: No ]
• The number and percentage of subjects in each treatment group recorded as a microbiological eradication or persistence or indeterminate. [ Time Frame: Multiple visits up until the Late Follow Up (28-35 Days after completion of study drug administration) ] [ Designated as safety issue: No ]
• For each unique pathogen, the number and percentage of subjects in each treatment group recorded as a microbiologic eradication or persistence for that particular pathogen. [ Time Frame: Late Follow Up (28-35 Days after completion of study drug administration) ] [ Designated as safety issue: No ]
• Safety will be evaluated in the safety population by presenting summaries of AEs, laboratory evaluations, vital signs, and physical examinations in the 2 treatment groups. [ Time Frame: All study visits through the Late Follow Up (28-35 Days after completion of study drug administration) ] [ Designated as safety issue: Yes ]

• The proportion of subjects (CXA 201 versus levofloxacin) who have both a per-subject microbiological outcome of eradication and a clinical outcome of cure in the ME at TOC population at the TOC visit. [ Time Frame: Test of Cure Visit (7 Days [± 2 days] after completion of study drug administration) ] [ Designated as safety issue: No ]
  The composite microbiological eradication and clinical cure rate, which is defined as the proportion of subjects (CXA 201 versus levofloxacin) who have both a per-subject microbiological outcome of eradication and a clinical outcome of cure in the ME at TOC population at the TOC visit will be calculated.
• The number and percentage of subjects in each treatment group recorded as a clinical cure or failure or indeterminate. [ Time Frame: Multiple visits up until the Late Follow Up (28-35 Days after completion of study drug administration) ] [ Designated as safety issue: No ]
  Clinical response CXA 201 versus comparator (levofloxacin) at the end of therapy (EOT), test-of-cure (TOC), and late follow up (LFU; 28 35 days post last dose of study drug) visits
• The number and percentage of subjects in each treatment group recorded as a microbiological eradication or persistence or indeterminate. [ Time Frame: Multiple visits up until the Late Follow Up (28-35 Days after completion of study drug administration) ] [ Designated as safety issue: No ]
  Microbiological response of CXA 201 versus comparator (levofloxacin) at the end of therapy (EOT), test-of-cure (TOC), and late follow up (LFU; 28-35 days post last dose of study drug) visits
• For each unique pathogen, the number and percentage of subjects in each treatment group recorded as a microbiologic eradication or persistence for that particular pathogen. [ Time Frame: Late Follow Up (28-35 Days after completion of study drug administration) ] [ Designated as safety issue: No ]
  Per-pathogen microbiological eradication rates
• Safety will be evaluated in the safety population by presenting summaries of AEs, laboratory evaluations (coagulation, hematology, chemistry evaluations, and urinalysis), vital signs, and physical examinations in the 2 treatment groups. [ Time Frame: All study visits through the Late Follow Up (28-35 Days after completion of study drug administration) ] [ Designated as safety issue: Yes ]

  Safety will be evaluated in the safety population through review of summaries of :

  • AEs
  • Laboratory evaluations
  • Vital signs
  • Physical examinations

This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of CXA 201 IV infusions (1500 mg q8h) versus levofloxacin IV infusions (750 mg qd) for the treatment of adults with a cUTI (including pyelonephritis).

Approximately 776 subjects will be enrolled into this study and randomized 1:1 to receive CXA-201 or comparator (levofloxacin) resulting in 330 subjects per treatment arm. Subject participation will require a minimum commitment of 35 days and a maximum of 42 days. Subjects will be hospitalized for the administration of all doses of IV study therapy. A test of cure visit will occur at 7 days after the last dose of study drug and a late follow-up evaluation or contact will occur a minimum of 28 days and a maximum of 35 days after the last dose of study drug.

• Complicated Urinary Tract Infection
• Pyelonephritis

• Drug: CXA-201
  CXA-201 IV infusion (1500mg q8) for 7 days
• Drug: Levofloxacin
  Levofloxacin IV infusion (750mg qd) for 7 days

• Experimental: CXA-201 as treatment for cUTI
  CXA-201 IV infusion (1500mg q8) for 7 days
  Intervention: Drug: CXA-201
• Active Comparator: Levofloxacin as treatment for cUTI
  Levofloxacin IV infusion (750mg qd) for 7 days
  Intervention: Drug: Levofloxacin

Inclusion Criteria:

1. Provide written informed consent prior to any study-related procedure not part of normal medical care (a legally acceptable representative may provide consent if the subject is unable to do so, provided this is approved by local country and institution specific guidelines).
2. Be males or females ≥ 18 years of age

3. If female, subject is non-lactating, and is either:

   1. Not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy; or
   2. Of childbearing potential and is practicing a barrier method of birth control (e.g., a diaphragm or contraceptive sponge) along with 1 of the following methods: oral or parenteral contraceptives (for 3 months prior to study drug administration), or a vasectomized partner. Or, subject is practicing abstinence from sexual intercourse. Subjects must be willing to practice these methods for the duration of the trial and for at least 35 days after last dose of study medication.
4. Males are required to practice reliable birth control methods (condom or other barrier device) during the conduct of the study and for at least 35 days after last dose of study medication.
5. Pyuria (white blood cell [WBC] count > 10/μL in unspun urine or ≥ 10 per high power field in spun urine).

6. Clinical signs and/or symptoms of cUTI, either of:

   1. Pyelonephritis, as indicated by at least 2 of the following:

      • Documented fever (oral temperature > 38°C) accompanied by patient symptoms of rigors, chills, or "warmth";
      • Flank pain;
      • Costovertebral angle tenderness or suprapubic tenderness on physical exam; or
      • nausea or vomiting; OR

   2. Complicated lower UTI, as indicated by at least 2 of the following:

      • At least 2 of the following new or worsening symptoms of cUTI:

        • Dysuria; urinary frequency or urinary urgency;
        • Documented fever (oral temperature > 38°C) accompanied by patient symptoms of rigors, chills, or "warmth";
        • Suprapubic pain or flank pain;
        • Costovertebral angle tenderness or suprapubic tenderness on physical exam; or
        • Nausea or vomiting; plus,

      • At least 1 of the following complicating factors:

        • Males with documented history of urinary retention;
        • Indwelling urinary catheter that is scheduled to be removed during IV study therapy and before the EOT;
        • Current obstructive uropathy that is scheduled to be medically or surgically relieved during IV study therapy and before the EOT; or
        • Any functional or anatomical abnormality of the urogenital tract (including anatomic malformations or neurogenic bladder) with voiding disturbance resulting in at least 100 mL residual urine.

7. Have a pretreatment baseline urine culture specimen obtained within 24 hours before the start of administration of the first dose of study drug.

   NOTE: Subjects may be enrolled in this study and start IV study drug therapy before the Investigator knows the results of the baseline urine culture.

8. Require IV antibacterial therapy for the treatment of the presumed cUTI.

Exclusion Criteria:

1. Have a documented history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam or quinilone antibacterial (Note: for β-lactams, a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment)
2. Have a concomitant infection at the time of randomization, which requires non-study systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only gram-positive activity [e.g., vancomycin, linezolid] are allowed.)
3. Receipt of any amount of potentially therapeutic antibacterial therapy after collection of the pretreatment baseline urine culture and before administration of the first dose of study drug.
4. Receipt of any dose of a potentially therapeutic antibacterial agent for the treatment of the current UTI within 48 hours before the study-qualifying pretreatment baseline urine is obtained (exceptions: subjects with an active cUTI who have received prior antibiotics may be enrolled provided a minimum of 48 hours have elapsed between the last dose of the prior antibiotic and the time of obtaining the baseline urine specimen. Subjects receiving current antibiotic prophylaxis for cUTI who present with signs and symptoms consistent with an active new cUTI may be enrolled provided all other eligibility criteria are met including obtaining a pre-treatment qualifying baseline urine culture).
5. Intractable urinary infection at baseline that the Investigator anticipates would require more than 7 days of study drug therapy.
6. Complete, permanent obstruction of the urinary tract.
7. Confirmed fungal urinary tract infection at time of randomization (with ≥ 103 fungal CFU/mL).
8. Permanent indwelling bladder catheter or urinary stent including nephrostomy.
9. Suspected or confirmed perinephric or intrarenal abscess.
10. Suspected or confirmed prostatitis.
11. Ileal loop or known vesico-ureteral reflux.
12. Severe impairment of renal function including an estimated CrCl < 30 mL/min, requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (< 20 mL/h urine output over 24 hours).
13. Current urinary catheter that is not scheduled to be removed before the EOT (intermittent straight catheterization during the IV study drug administration period is acceptable).
14. Any condition or circumstance that, in the opinion of the Investigator, would compromise the safety of the subject or the quality of study data.
15. Any rapidly progressing disease or immediately life-threatening illness including acute hepatic failure, respiratory failure, and septic shock.
16. Immunocompromising condition, including established AIDS, hematological malignancy, or bone marrow transplantation, or immunosuppressive therapy including cancer chemotherapy, medications for prevention of organ transplantation rejection, or the administration of corticosteroids equivalent to or greater than 40 mg of prednisone per day administered continuously for more than 14 days preceding randomization.
17. One or more of the following laboratory abnormalities in baseline specimens: aspartate aminotransferase (AST [SGOT]), alanine aminotransferase (ALT [SGPT]), alkaline phosphatase, or total bilirubin level greater than 3 times the upper limit of normal (ULN), absolute neutrophil count less than 500/μL, platelet count less than 40,000/μL, or hematocrit less than 20%.
18. Participation in any clinical study of an investigational product within 30 days prior to the proposed first day of study drug.
19. Previous participation in any study of CXA-101 or CXA-201.
20. Women who are pregnant or nursing.